摘要
目的探讨血清鳞状细胞癌抗原(SCCA)、癌胚抗原(CEA)、促胃泌素释放肽前体(ProGRP)表达对肺癌化疗患者预后的评估价值。方法回顾性分析62例肺癌患者(肺癌组)、35例肺炎患者(对照组)、30例健康志愿者(健康组)的临床资料,比较三组血清SCCA、CEA、ProGRP表达水平,分析血清SCCA、CEA、ProGRP表达水平与肺癌患者病理特征及随访预后的关系,ROC曲线分析血清SCCA、CEA、ProGRP表达对肺癌化疗患者预后的评估价值。结果肺癌组血清SCCA、CEA、ProGRP表达水平较对照组、健康组均明显高,且对照组也高于健康组(P<0.05);肺癌患者血清SCCA、CEA、ProGRP表达水平在生存情况、复发情况方面有明显的差异,其中死亡者、复发者明显高于存活及无复发者(P<0.05);SCCA+CEA+ProGRP联合检测在肺癌患者预后生存情况和复发情况诊断的曲线下面积明显大于各自单一检测的。结论血清SCCA、CEA、ProGRP联合检测能够明显提高对肺癌化疗患者预后的评估效能,或可作为肺癌患者化疗疗效评估的有效方案。
Objective To investigate the value of serum squamous cell carcinoma antigen(SCCA),carcinoembryonic antigen(CEA)and progastrin-releasing peptide(ProGRP)in evaluating the prognosis of patients with lung cancer undergoing chemotherapy.Methods The clinical data of 62 patients with lung cancer(lung cancer group),35 patients with pneumonia(control group)and 30 healthy volunteers(healthy group)were retrospectively analyzed.The expression levels of serum SCCA,CEA and ProGRP were compared among the three groups.The association of expression levels of serum SCCA,CEA and ProGRP with pathological characteristics of lung cancer and follow-up prognosis was analyzed.ROC curve was used to analyze the value of serum SCCA,CEA and ProGRP for evaluating the prognosis of the cancer patients.Results The expression levels of serum SCCA,CEA and ProGRP in the lung cancer group were significantly higher than those in the control group and the healthy group,and the levels in the control group were also significantly higher than those in the healthy group(P<0.05).The expression levels of serum SCCA,CEA and ProGRP in lung cancer patients were significantly different under different status of survive and recurrence.The levels in dead or recurrent patients were significantly higher than those in survival patients or without recurrence(P<0.05).The areas under the ROC curve of combined detection of SCCA,CEA and ProGRP for evaluating the prognosis and recurrence of lung cancer were significantly larger than those of individual detection.Conclusion The combined detection of serum SCCA,CEA and ProGRP can significantly improve the evaluation efficiency for prognosis of patients with lung cancer undergoing chemotherapy.It can be used as an effective method for evaluating the curative effect of chemotherapy in patients with lung cancer.
作者
古晓娟
张映华
唐欢
GU Xiao-juan;ZHANG Ying-hua;TANG Huan(Department of Respiratory Medicine,Yibin Second People's Hospital,Yibin 644000,China)
出处
《实用医院临床杂志》
2019年第5期230-233,共4页
Practical Journal of Clinical Medicine